Hainan Poly Pharm First Quarter 2024 Earnings: EPS: CN¥0.15 (vs CN¥0.15 in 1Q 2023)
Hainan Poly Pharm (SZSE:300630) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥306.3m (up 43% from 1Q 2023).
- Net income: CN¥66.7m (flat on 1Q 2023).
- Profit margin: 22% (down from 31% in 1Q 2023).
- EPS: CN¥0.15 (in line with 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hainan Poly Pharm shares are down 37% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with Hainan Poly Pharm (including 2 which are a bit unpleasant).
Valuation is complex, but we're here to simplify it.
Discover if Hainan Poly Pharm might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:300630
Hainan Poly Pharm
Engages in the research and development, production, and sale of pharmaceutical drugs in China and internationally.
Moderate with moderate growth potential.
